頁籤選單縮合
題名 | 2010~2012年流感抗病毒藥劑Peramivir用藥分析=Analysis of Intravenous Peramivir for Treatment of Seasonal Influenza Infections, Taiwan, 2010~2012 |
---|---|
作者 | 蔡筱芸; 林美凌; 池宜倩; 周淑玫; 陳昶勳; 楊靖慧; Tsai, Hsiao-yun; Lin, Mei-ling; Chih, Yi-chien; Chou, Shu-mei; Chen, Chang-hsun; Yang, Chin-hui; |
期刊 | 疫情報導 |
出版日期 | 20131105 |
卷期 | 29:21 2013.11.05[民102.11.05] |
頁次 | 頁329-335 |
分類號 | 418.285 |
語文 | chi、eng |
關鍵詞 | 流感抗病毒藥劑; 流感併發症; Peramivir; Antivirals; Severe complicated influenza; |
中文摘要 | Peramivir為新研發之點滴注射劑型神經胺酸酶抑制劑類流感抗病毒藥劑,可用以治療 A型或 B型流感病毒感染,該藥目前在國內尚未領有上市許可證,故使用前須取得病患或家屬同意,由於靜脈注射使用需醫療專業,且藥劑單價較高,故疾病管制局(現已改制為疾病管制署)從 2010年起自日本專案進口之peramivir,主要係提供流感併發症患者因昏迷等原因致無法吞服或吸入其他抗病毒藥劑之符合公費抗病毒藥劑使用對象者,作為投藥之藥劑選項之一,以因應該類病患無法吞服克流感(oseltamivir)或吸入瑞樂沙(zanamivir)等抗病毒藥劑之防疫及治療需求,並符合我國抗病毒藥劑多元儲備策略;而其他公費用藥對象仍優先以克流感或瑞樂沙做早期投藥,故推測投予peramivir之病患應為病程較嚴重之病患。本文統計2010-2011年及2011-2012年流感季經傳染病防治醫療網區指揮官同意用藥之 68個病例,使用量共 439袋,與當季流感併發症確定病例人數分別為1,784例(死亡140例)及1,704例(死亡154例)相較,顯示使用 peramivir的病患並不多,因此,未來仍需宣導第一線醫師有需要時可多加利用此防疫資源,因目前 peramivir確實是提供無法吞服或吸入流感抗病毒藥劑之重症個案治療之惟一替代性藥物選擇。 |
英文摘要 | Peramivir is a newly developed intravenous administrated neuraminidase inhibitor used to treat influenza, effective against both influenza A and influenza B infections. It is not approved in Taiwan yet, so a patient’s or family’s consent is required before administration. Taiwan Centers for Disease Control (Taiwan CDC) started to import peramivir from Japan under special permit since 2010. Oral and inhaled antivirals, Tamiflu (oseltamivir) and Relenza (zanamivir) in respective, are the first choices of treatment in influenza patients qualified for government-funded antivirals. Peramivir was imported to treat patients who cannot take Tamiflu orally or inhale Relenza due to unconsciousness or other morbidities, and to build a diverse stockpile of antivirals for our country. Because only physicians can prescribe intravenous injection and the price of the drug is high, peramivir is only used in qualified patients with severe complicated influenza. In this article, we analyzed 68 patients who had been treated with peramivir during 2010-2011 or 2011-2012 influenza seasons after obtaining permission from the district commander of the Communicable Disease Control Medical Network. Four hundred and thirty-nine packs were used. Compared with the number of patients with confirmed complicated influenza infection in two flu seasons, 1,784 in 2010-2011 and 1,704 in 2011-2012, and the number of death, 140 and 154 deaths in respective, the number of patients using peramivir was relatively small. More education on primary care physicians about the timing of peramivir usage is needed, because it is the only alternative in severe patients who cannot take orally or inhale other medications. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。